Biopharma’s COVID Capital Comeback – A Whitepaper

What a difference a few months can make – especially during a pandemic. Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big...

Panel Recording: The Unexpected IPO Boom in Biopharma in Q2

Locust Walk partnered with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd. Q2 saw a boom in IPOs, while many biopharma companies continue to seek capital in both public and private markets, including multiple...

Deal Makers of Japan, Volume 2, Exclusive Interviews

We are pleased to present the second series of the Deal Makers of Japan – Exclusive Interviews with Japan’s best dealmakers. We released our inaugural edition in March 2020 and have received numerous comments from biotech/biopharma companies around the world. Since...

Live Panel: The Unexpected IPO Boom for Biopharma in Q2

Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled “The Unexpected IPO Boom for Biopharma in Q2.” CLICK HERE TO REGISTER Q2 saw a boom in IPOs, while...

Q2 2020 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2020 Report applies the latest data to analyze current activities in the life science deal landscape.